284 related articles for article (PubMed ID: 35963845)
1. ACSL4-dependent ferroptosis does not represent a tumor-suppressive mechanism but ACSL4 rather promotes liver cancer progression.
Grube J; Woitok MM; Mohs A; Erschfeld S; Lynen C; Trautwein C; Otto T
Cell Death Dis; 2022 Aug; 13(8):704. PubMed ID: 35963845
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic regulation of ferroptosis via ETS1/miR-23a-3p/ACSL4 axis mediates sorafenib resistance in human hepatocellular carcinoma.
Lu Y; Chan YT; Tan HY; Zhang C; Guo W; Xu Y; Sharma R; Chen ZS; Zheng YC; Wang N; Feng Y
J Exp Clin Cancer Res; 2022 Jan; 41(1):3. PubMed ID: 34980204
[TBL] [Abstract][Full Text] [Related]
3. ACSL4 is a predictive biomarker of sorafenib sensitivity in hepatocellular carcinoma.
Feng J; Lu PZ; Zhu GZ; Hooi SC; Wu Y; Huang XW; Dai HQ; Chen PH; Li ZJ; Su WJ; Han CY; Ye XP; Peng T; Zhou J; Lu GD
Acta Pharmacol Sin; 2021 Jan; 42(1):160-170. PubMed ID: 32541921
[TBL] [Abstract][Full Text] [Related]
4. High-fat diet impairs ferroptosis and promotes cancer invasiveness via downregulating tumor suppressor ACSL4 in lung adenocarcinoma.
Zhang Y; Li S; Li F; Lv C; Yang QK
Biol Direct; 2021 May; 16(1):10. PubMed ID: 34053456
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of ACSL4 attenuates ferroptotic damage after pulmonary ischemia-reperfusion.
Xu Y; Li X; Cheng Y; Yang M; Wang R
FASEB J; 2020 Dec; 34(12):16262-16275. PubMed ID: 33070393
[TBL] [Abstract][Full Text] [Related]
6. MitoQ protects against carbon tetrachloride-induced hepatocyte ferroptosis and acute liver injury by suppressing mtROS-mediated ACSL4 upregulation.
Tao L; Xue YF; Sun FF; He X; Wang HQ; Tong CC; Zhang C; Xu DX; Chen X
Toxicol Appl Pharmacol; 2024 May; 486():116914. PubMed ID: 38522585
[TBL] [Abstract][Full Text] [Related]
7. ATF4 suppresses hepatocarcinogenesis by inducing SLC7A11 (xCT) to block stress-related ferroptosis.
He F; Zhang P; Liu J; Wang R; Kaufman RJ; Yaden BC; Karin M
J Hepatol; 2023 Aug; 79(2):362-377. PubMed ID: 36996941
[TBL] [Abstract][Full Text] [Related]
8. HCAR1/MCT1 Regulates Tumor Ferroptosis through the Lactate-Mediated AMPK-SCD1 Activity and Its Therapeutic Implications.
Zhao Y; Li M; Yao X; Fei Y; Lin Z; Li Z; Cai K; Zhao Y; Luo Z
Cell Rep; 2020 Dec; 33(10):108487. PubMed ID: 33296645
[TBL] [Abstract][Full Text] [Related]
9. RB1-deficient prostate tumor growth and metastasis are vulnerable to ferroptosis induction via the E2F/ACSL4 axis.
Wang ME; Chen J; Lu Y; Bawcom AR; Wu J; Ou J; Asara JM; Armstrong AJ; Wang Q; Li L; Wang Y; Huang J; Chen M
J Clin Invest; 2023 May; 133(10):. PubMed ID: 36928314
[TBL] [Abstract][Full Text] [Related]
10. The positive feedback between ACSL4 expression and O-GlcNAcylation contributes to the growth and survival of hepatocellular carcinoma.
Wang J; Wang Z; Yuan J; Wang J; Shen X
Aging (Albany NY); 2020 May; 12(9):7786-7800. PubMed ID: 32357142
[TBL] [Abstract][Full Text] [Related]
11. SIAH2-Mediated Degradation of ACSL4 Inhibits the Anti-Tumor Activity of CD8+ T Cells in Hepatocellular Carcinoma.
Shu F; Shi Y; Shan X; Zha W; Fan R; Xue W
Crit Rev Eukaryot Gene Expr; 2024; 34(5):1-13. PubMed ID: 38842200
[TBL] [Abstract][Full Text] [Related]
12. Ischemia-induced ACSL4 activation contributes to ferroptosis-mediated tissue injury in intestinal ischemia/reperfusion.
Li Y; Feng D; Wang Z; Zhao Y; Sun R; Tian D; Liu D; Zhang F; Ning S; Yao J; Tian X
Cell Death Differ; 2019 Nov; 26(11):2284-2299. PubMed ID: 30737476
[TBL] [Abstract][Full Text] [Related]
13. Tumor suppressor miR-424-5p abrogates ferroptosis in ovarian cancer through targeting ACSL4.
Ma LL; Liang L; Zhou D; Wang SW
Neoplasma; 2021 Jan; 68(1):165-173. PubMed ID: 33038905
[TBL] [Abstract][Full Text] [Related]
14. ACSL4 promotes malignant progression of Hepatocellular carcinoma by targeting PAK2 transcription.
Wu D; Zuo Z; Sun X; Li X; Yin F; Yin W
Biochem Pharmacol; 2024 Jun; 224():116206. PubMed ID: 38615921
[TBL] [Abstract][Full Text] [Related]
15. ALKBH5 targets ACSL4 mRNA stability to modulate ferroptosis in hyperbilirubinemia-induced brain damage.
Zhou J; Tang J; Zhang C; Li G; Lin X; Liao S; Luo J; Yu G; Zheng F; Guo Z; Shao W; Hu H; Xu L; Wu S; Li H
Free Radic Biol Med; 2024 Aug; 220():271-287. PubMed ID: 38734267
[TBL] [Abstract][Full Text] [Related]
16. Impact of ACSL4 on the prognosis of hepatocellular carcinoma: Association with cancer-associated fibroblasts and the tumour immune microenvironment.
Toshida K; Itoh S; Iseda N; Tomiyama T; Yoshiya S; Toshima T; Liu YC; Iwasaki T; Okuzaki D; Taniguchi K; Oda Y; Mori M; Yoshizumi T
Liver Int; 2024 Apr; 44(4):1011-1023. PubMed ID: 38293713
[TBL] [Abstract][Full Text] [Related]
17. Necroptosis and ferroptosis are alternative cell death pathways that operate in acute kidney failure.
Müller T; Dewitz C; Schmitz J; Schröder AS; Bräsen JH; Stockwell BR; Murphy JM; Kunzendorf U; Krautwald S
Cell Mol Life Sci; 2017 Oct; 74(19):3631-3645. PubMed ID: 28551825
[TBL] [Abstract][Full Text] [Related]
18. ACSL4 deficiency confers protection against ferroptosis-mediated acute kidney injury.
Wang Y; Zhang M; Bi R; Su Y; Quan F; Lin Y; Yue C; Cui X; Zhao Q; Liu S; Yang Y; Zhang D; Cao Q; Gao X
Redox Biol; 2022 May; 51():102262. PubMed ID: 35180475
[TBL] [Abstract][Full Text] [Related]
19. Gp78 deficiency in hepatocytes alleviates hepatic ischemia-reperfusion injury via suppressing ACSL4-mediated ferroptosis.
Li C; Wu Y; Chen K; Chen R; Xu S; Yang B; Lian Z; Wang X; Wang K; Xie H; Zheng S; Liu Z; Wang D; Xu X
Cell Death Dis; 2023 Dec; 14(12):810. PubMed ID: 38065978
[TBL] [Abstract][Full Text] [Related]
20. ACSL4 suppresses glioma cells proliferation via activating ferroptosis.
Cheng J; Fan YQ; Liu BH; Zhou H; Wang JM; Chen QX
Oncol Rep; 2020 Jan; 43(1):147-158. PubMed ID: 31789401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
